Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application

다국어 초록 (Multilingual Abstract)

Virus-like particles (VLPs) are viral structural protein that are noninfectious as they do not contain viral genetic materials. They are safe and effective immune stimulators and play important roles in vaccine development because of their intrinsic immunogenicity to induce cellular and humoral immune responses. In the design of antiviral vaccine, VLPs based vaccines are appealing multifunctional candidates with the advantages such as self-assembling nanoscaled structures, repetitive surface epitopes, ease of genetic and chemical modifications, versatility as antigen presenting platforms, intrinsic immunogenicity, higher safety profile in comparison with live-attenuated vaccines and inactivated vaccines. In this review, we discuss the mechanism of VLPs vaccine inducing cellular and humoral immune responses. We outline the impact of size, shape, surface charge, antigen presentation, genetic and chemical modification, and expression systems when constructing effective VLPs based vaccines. Recent applications of antiviral VLPs vaccines and their clinical trials are summarized.

참고문헌 (Reference)

1 Boland, B., "beta-Amyloid (1-40)-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-ADP-ribose polymerase" 24 : 179-186, 2003

2 Shahrivarkevishahi, A., "Viruslike particles: a self-assembled toolbox for cancer therapy" 24 : 100808-, 2022

3 Andersson, A. C., "Virus-like-vaccines against HIV" 6 : 10-, 2018

4 Grgacic, E. V., "Virus-like particles:passport to immune recognition" 40 : 60-65, 2006

5 Peacey, M., "Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response" 26 : 5334-5337, 2008

6 Chroboczek, J., "Virus-like particles as vaccine" 61 : 531-539, 2014

7 Kushnir, N., "Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development" 31 : 58-83, 2012

8 Yadav, R., "Virus-like particlebased L2 vaccines against HPVs: where are we today?" 12 : 18-, 2019

9 Donaldson, B., "Virus-like particle vaccines: immunology and formulation for clinical translation" 17 : 833-849, 2018

10 Ding, X., "Virus-like particle engineering: from rational design to versatile applications" 13 : e1700324-, 2018

11 Chackerian, B., "Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model" 180 : 5816-5825, 2008

12 Plummer, E. M., "Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design" 3 : 174-196, 2011

13 Chen, Z., "Viral chemistry: the chemical functionalization of viral architectures to create new technology" 8 : 512-534, 2016

14 Rerks-Ngarm, S., "Vaccination with ALVAC and AIDSVAX to prevent HIV-1infection in Thailand" 361 : 2209-2220, 2009

15 Davis, M. E., "Ubiquitination in the antiviral immune response" 479-480 : 52-65, 2015

16 Boonyakida, J., "Two-step purification of tag-free norovirus-like particles from silkworm larvae (Bombyx mori)" 190 : 106010-, 2022

17 van Oosten, L., "Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2variants" 12 : e0181321-, 2021

18 Vaculová, A., "Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells" 22 : 1635-1639, 2002

19 Ortega-Rivera, O. A., "Trivalent subunit vaccine candidates for COVID-19 and their delivery devices" 143 : 14748-14765, 2021

20 Braz Gomes, K., "Transdermal vaccination with the matrix-2 protein virus-like particle (M2e VLP) induces immunity in mice against influenza A virus" 9 : 1324-, 2021

21 Loganathan, R., "Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity" 46 : 203-213, 2013

22 Valerdi, K. M., "The role of the host ubiquitin system in promoting replication of emergent viruses" 13 : 369-, 2021

23 Aslan Koşar, P., "The efficiency of poly(ADP-Ribose) polymerase (PARP) cleavage on detection of apoptosis in an experimental model of testicular torsion" 96 : 294-300, 2015

24 Foss, S., "TRIM21-from intracellular immunity to therapy" 10 : 2049-, 2019

25 van Gent, M., "TRIM proteins and their roles in antiviral host defenses" 5 : 385-405, 2018

26 Liu, D., "Sublingual immunization with chimeric C1q/CD40ligand/HIV virus-like particles induces strong mucosal immune responses against HIV" 9 : 1236-, 2021

27 Pol, S., "Specific vaccine therapy in chronic hepatitis B infection" 344 : 342-, 1994

28 Malm, M., "Simultaneous immunization with multivalent norovirus VLPs induces better protective immune responses to norovirus than sequential immunization" 11 : 1018-, 2019

29 Escolano, A., "Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env" 13 : eabk1533-, 2021

30 Wikman, M., "Selection and characterization of HER2/neu-binding affibody ligands" 17 : 455-462, 2004

31 Macartney, K. K., "Safety of human papillomavirus vaccines: a review" 36 : 393-412, 2013

32 Yu, H., "STATs in cancer inflammation and immunity: a leading role for STAT3" 9 : 798-809, 2009

33 Ku, C. R., "Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase" 59 : 103-109, 2012

34 Nord, K., "Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A" 268 : 4269-4277, 2001

35 Yap, I., "Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity" 10 : 439-442, 1992

36 Suh, D., "Recent applications of deep learning methods on evolution- and contact-based protein structure prediction" 22 : 6032-, 2021

37 Wang, D., "Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles" 11 : 2841-, 2020

38 DeFazio-Eli, L., "Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action" 13 : R44-, 2011

39 Woo, E. J., "Postmarketing safety surveillance of trivalent recombinant influenza vaccine: reports to the vaccine adverse event reporting system" 35 : 5618-5621, 2017

40 Jones, M. W., "Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents" 134 : 1847-1852, 2012

41 Ward, B. J., "Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19" 27 : 1071-1078, 2021

42 Bartek, J., "Pathways governing G1/S transition and their response to DNA damage" 490 : 117-122, 2001

43 Akira, S., "Pathogen recognition and innate immunity" 124 : 783-801, 2006

44 Zhang, P., "Oleanolic acid induces apoptosis in human leukemia cells through caspase activation and poly(ADP-ribose) polymerase cleavage" 39 : 803-809, 2007

45 Rodríguez-Hernández, A., "Nuclear caspase-3 and caspase-7 activation, and poly(ADPribose)polymerase cleavage are early events in camptothecininduced apoptosis" 11 : 131-139, 2006

46 Jimenez-Moyano, E., "Nonhuman TRIM5 variants enhance recognition of HIV-1-infected cells by CD8+ T cells" 90 : 8552-8562, 2016

47 Morón, G., "New tools for antigen delivery to the MHC class I pathway" 25 : 92-97, 2004

48 Smith, G. E., "Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets" 509 : 90-97, 2017

49 Kim, K. H., "Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus" 535 : 179-188, 2019

50 Peek, L. J., "Nanotechnology in vaccine delivery" 60 : 915-928, 2008

51 Manolova, V., "Nanoparticles target distinct dendritic cell populations according to their size" 38 : 1404-1413, 2008

52 Wacker, M., "N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli" 298 : 1790-1793, 2002

53 Kim, M. C., "Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection" 99 : 328-335, 2013

54 Kingstad-Bakke, B., "Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge" 33 : 5155-5162, 2015

55 Rueda, P., "Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles" 263 : 89-99, 1999

56 Nakahira, Y., "Mass production of virus-like particles using chloroplast genetic engineering for highly immunogenic oral vaccine against fish disease" 12 : 717952-, 2021

57 Mohsen, M. O., "Major findings and recent advances in virus-like particle (VLP)-based vaccines" 34 : 123-132, 2017

58 Leman, J. K., "Macromolecular modeling and design in Rosetta: recent methods and frameworks" 17 : 665-680, 2020

59 Bessa, J., "Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses" 109 : 20566-20571, 2012

60 Christoffer, C., "LZerD protein-protein docking webserver enhanced with de novo structure prediction" 8 : 724947-, 2021

61 Mohsen, M. O., "Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system" 6 : 37-, 2018

62 Zepeda-Cervantes, J., "Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs" 11 : 1100-, 2020

63 Song, J. M., "Influenza virus-like particles containing M2induce broadly cross protective immunity" 6 : e14538-, 2011

64 Pushko, P., "Influenza virus like particles (VLPs): opportunities for H7N9 vaccine development" 12 : 518-, 2020

65 Quan, F. S., "Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection" 430 : 127-135, 2012

66 Chapman, R., "Immunogenicity of HIV-1vaccines expressing chimeric envelope glycoproteins on the surface of Pr55 Gag virus-like particles" 8 : 54-, 2020

67 Veenstra, J., "Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons" 174 : 862-866, 1996

68 Panasiuk, M., "Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies" 20 : 186-, 2021

69 Yinjun, L., "Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP)" 76 : 199-204, 2004

70 Liu, W., "High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins" 35 : 505-514, 2005

71 Mikaeloff, Y., "Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood" 72 : 873-880, 2009

72 Mallajosyula, V. V., "Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype" 6 : 329-, 2015

73 Stanley, M., "HPV vaccines: alternative dosage schedules" 18 : 1309-1316, 2019

74 Pillay, S., "HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice" 8 : 7-, 2010

75 P Park, E. J., "Gonadotropin-releasing hormoneagonist induces apoptosis of human granulosa-luteal cells via caspase-8, -9 and -3, and poly-(ADP-ribose)-polymerase cleavage" 5 : 120-128, 2011

76 D'Amours, D., "Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis" 114 : 3771-3778, 2001

77 Han, J. C., "GII.P16-GII.2 recombinant norovirus VLPs polarize macrophages into the M1 phenotype for Th1immune responses" 12 : 781718-, 2021

78 Shoeb, E., "Future of cancer immunotherapy using plant virus-based nanoparticles" 5 : FSO401-, 2019

79 Destito, G., "Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells" 14 : 1152-1162, 2007

80 Chen, Z., "Fluorescent functionalization across quaternary structure in a virus-like particle" 28 : 2277-2283, 2017

81 Eto, Y., "Expression of chimeric HPV-HIV protein L1P18 in Pichia pastoris; purification and characterization of the virus-like particles" 13 : 1967-, 2021

82 정호철 ; 성백린, "Exploiting virus-like particles as innovative vaccines against emerging viral infections" 한국미생물학회 55 (55): 220-230, 2017

83 Mahfouz, R. Z., "Evaluation of poly(ADPribose)polymerase cleavage (cPARP) in ejaculated human sperm fractions after induction of apoptosis" 91 : 2210-2220, 2009

84 Zuckerman, J. N., "Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines" 34 : 798-802, 2001

85 Ching, J. C., "Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspases" 70 : 4669-4677, 2002

86 Chevillard, C., "Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform" 30 : 1913-1925, 2022

87 Schwarz, K., "Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles" 35 : 816-821, 2005

88 Sherwood, J., "Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults" 38 : 6442-6449, 2020

89 Chen, G. L., "Effect of a Chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial" 323 : 1369-1377, 2020

90 Sieczkarski, S. B., "Dissecting virus entry via endocytosis" 83 : 1535-1545, 2002

91 Kitazawa, M., "Dieldrin promotes proteolytic cleavage of poly(ADP-ribose) polymerase and apoptosis in dopaminergic cells: protective effect of mitochondrial anti-apoptotic protein Bcl-2" 25 : 589-598, 2004

92 Royal, J. M., "Development of a SARS-CoV-2 vaccine candidate using plant-based manufacturing and a tobacco mosaic viruslike nano-particle" 9 : 1347-, 2021

93 Nieto, K., "Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate" 7 : e39741-, 2012

94 Ao, Z., "Development and evaluation of an Ebola virus glycoprotein mucin-like domain replacement system as a new dendritic cell-targeting vaccine approach against HIV-1" 95 : e0236820-, 2021

95 Wiersma, L. C., "Developing universal influenza vaccines: hitting the nail, not just on the head" 3 : 239-262, 2015

96 Bárcena, J., "Design of novel vaccines based on virus-like particles or chimeric virions" 68 : 631-665, 2013

97 Chen, C. W., "Design concepts of virus-like particle-based HIV-1 vaccines" 11 : 573157-, 2020

98 Larsson, M., "DC-virus interplay: a double edged sword" 16 : 147-161, 2004

99 Utaisincharoen, P., "CpG ODN enhances uptake of bacteria by mouse macrophages" 132 : 70-75, 2003

100 Zeltins, A., "Construction and characterization of viruslike particles: a review" 53 : 92-107, 2013

101 Daniell, H., "Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes" 17 : 1357-1368, 2019

102 Pucci, B., "Cell cycle and apoptosis" 2 : 291-299, 2000

103 Yang, Y., "Caspase-dependent apoptosis and -independent poly(ADP-ribose) polymerase cleavage induced by transforming growth factor beta1" 36 : 223-234, 2004

104 F Fougeroux, C., "Capsid-like particles decorated with the SARS-CoV-2receptor-binding domain elicit strong virus neutralization activity" 12 : 324-, 2021

105 Aljabali, A. A., "CPMV-DOX delivers" 10 : 3-10, 2013

106 Yin, Z., "Boosting immunity to small tumorassociated carbohydrates with bacteriophage qβ capsids" 8 : 1253-1262, 2013

107 Menne, Z., "Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model" 562 : 197-208, 2021

108 Yang, R., "B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88" 174 : 7912-7919, 2005

109 Hennequin, B., "Aqueous near-infrared fluorescent composites based on apoferritinencapsulated PbS quantum dots" 20 : 3592-3596, 2008

110 Heinimäki, S., "Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology" 566 : 89-97, 2022

111 Schwartzman, L. M., "An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus" 6 : e01044-, 2015

112 Fluckiger, A. C., "An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity" 39 : 4988-5001, 2021

113 Nygren, P. A., "Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold" 275 : 2668-2676, 2008

114 Qawasmi, M., "Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood" 11 : 1717-1724, 2015

115 Grönwall, C., "Affibody-mediated transferrin depletion for proteomics applications" 2 : 1389-1398, 2007

116 Pal, H. C., "Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa" 24 : 1599-1609, 2010

117 Peters, B. S., "A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects" 35 : 231-235, 1997

118 Guo, C., "A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates" 2 : 100448-, 2021

119 Thrane, S., "A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA" 10 : e0143071-, 2015

120 Chang, X., "A novel double mosaic virus-like particle-based vaccine against SARSCoV-2 incorporates both receptor binding motif (RBM) and fusion domain" 9 : 1287-, 2021

121 Zhai, L., "A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9" 147 : 116-123, 2017

122 Yang, J. R., "A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses" 126 : 8-17, 2016

123 Zhang, P., "A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques" 27 : 2234-2245, 2021

124 Dalvie, N. C., "A modular protein subunit vaccine candidate produced in yeast confers protection against SARSCoV-2 in non-human primates"

125 Xie, H., "A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice" 200 : 1874-1883, 2009

126 Hemmi, H., "A Toll-like receptor recognizes bacterial DNA" 408 : 740-745, 2000